Обзор и прогноз мирового рынка серповидноклеточной анемии до 2031 года — анализ рынка и доля рынка

Обзор мирового рынка серповидноклеточной анемии

По данным Центров по контролю и профилактике заболеваний США, серповидноклеточная анемия (SCD) поражает около 100 000 человек в Соединенных Штатах, что подчеркивает растущий спрос на эффективные методы лечения и решения по управлению на мировом рынке серповидноклеточной анемии. Эта растущая распространенность подчеркивает острую необходимость в передовых методах лечения и комплексных вариантах ухода для решения проблем, с которыми сталкиваются пациенты. Поскольку осведомленность и исследования SCD продолжают развиваться, рынок готов к значительному росту, обусловленному инновациями в лечении и улучшенными стратегиями управления заболеванием.

Отчет о рынке Data Bridge Market Research содержит сведения о последних разработках, доле рынка, тенденциях рынка на основе сегментации и регионального анализа, влиянии участников рынка, анализе возможностей с точки зрения новых источников дохода, изменениях в регулировании рынка, стратегическом анализе роста рынка, размере рынка, росте рынка категорий, нишах приложений и доминировании, одобрении продуктов, запуске продуктов, географическом расширении, технологических инновациях на рынке. Чтобы получить больше информации о рынке, свяжитесь с командой экспертов-аналитиков Data Bridge Market Research. Наша команда поможет вам принять обоснованные рыночные решения для достижения роста бизнеса.

Размер мирового рынка серповидноклеточной анемии

The Global Sickle Cell Disease Market is a dynamic and essential sector dedicated to meeting the medical needs of those affected by sickle cell disease (SCD). SCD is a genetic blood disorder marked by abnormal hemoglobin, which causes red blood cells to become rigid and crescent-shaped, leading to various complications and health challenges. This market focuses on advancing innovative therapies, medications, and supportive care options to enhance the quality of life for individuals living with SCD. As a result, Databridge Market Research dived into comprehensively analyzing the market and unveiled that the Global Sickle Cell Disease Market is increasing at a CAGR of 13.21%. Our detailed analysis forecasts that the market is valued at USD 2.79 billion in 2023 and is expected to grow upto USD 7.52 billion by 2031. Our meticulously created report, developed through comprehensive research and analytics, is a distinguished paper that unveils eye-opening data about the market.

Global Sickle Cell Disease Market Dynamics

Global Sickle Cell Disease Market Growth Drivers

Increasing prevalence of sickle cell disease

The increasing incidence of sickle cell disease worldwide is projected to contribute positively to market expansion. Sickle cell anemia exhibits both genotypic and phenotypic variations due to specific mutations in hemoglobin genes. Each year, around 300,000 infants are diagnosed with sickle cell disease, and an estimated 20 to 25 million individuals globally possess inherited sickle cell traits. The disease is particularly prevalent among individuals of African, Middle Eastern, and South Asian descent. Factors such as rising immigration rates, advancements in healthcare services, and a significant population of African descent are expected to propel the growth of the global market.

Growing investment in healthcare infrastructure

Significant factor influencing the growth rate of sickle cell disease market is the rising healthcare expenditure which helps in improving its infrastructure. For instance, according to WHO Global investment in health infrastructure was USD 9 trillion in 2020. Consequently, increased funding helps to advance research, develop new treatments, and improve patient care systems, thereby, driving the growth of the Global Sickle Cell Disease Market by facilitating the availability of innovative therapies and better management options for those affected by Sickle Cell Disease.

Global Sickle Cell Disease Market Growth Opportunities

Advancements in gene therapy

Advancements in gene therapy, particularly with the CRISPR-Cas9 technology, hold the potential to correct the genetic mutations responsible for Sickle Cell Disease (SCD). By enabling precise modification of the DNA sequence, CRISPR-Cas9 offers the possibility of a functional cure for SCD. CRISPR-Cas9's innovation represents a transformative opportunity for the Global Sickle Cell Disease Market, as it addresses a significant unmet medical need and is likely to drive substantial investment and regulatory support, fueling market growth.

Government and Non-Profit Initiatives

Government and non-profit initiatives are playing a pivotal role in driving the expansion of the Global Sickle Cell Disease Market. For instance, the U.S. government, through the National Institutes of Health (NIH), has committed over $100 million to the Cure Sickle Cell Initiative, which focuses on accelerating the development of genetic therapies. Substantial investment's not only supports cutting-edge research but also enhances the development and approval of innovative treatments. Consequently, significant opportunities cultivating market growth by fostering advancements in therapy options, increasing investor confidence, and improving access to treatment on a global scale.

Global Sickle Cell Disease Market Growth Challenges

High costs associated with Sickle Cell Disease restricting the market growth

High treatment costs present a significant barrier to the widespread adoption of advanced therapies for Sickle Cell Disease, particularly in low-income regions and underserved populations. For instance, gene therapy treatments like those using CRISPR-Cas9 can cost upwards of $1 million per patient. Patients in developing countries or low-income communities face challenges in accessing these potentially life-saving treatments, which hinders the overall growth and impact of the Global Sickle Cell Disease Market.

Lack of Awareness

Lack of awareness about Sickle Cell Disease (SCD) and treatment options is a major challenge, leading to delayed diagnoses and inadequate management. For instance, in sub-Saharan Africa, many individuals and healthcare providers lack knowledge about SCD, resulting in late diagnoses and severe complications. Similarly, in India, despite growing awareness efforts, a significant portion of the population remains uninformed, leading to suboptimal care. Addressing these awareness gaps is crucial for improving early diagnosis and treatment, thus driving market growth.

Global Sickle Cell Disease Market Growth Restraints

Increased regulations constraining the growth of the global Sickle Cell Disease market

Regulatory hurdles significantly impact the speed and cost of bringing new therapies for Sickle Cell Disease (SCD) to market. Navigating complex regulatory environments, such as those enforced by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), involves rigorous and lengthy approval processes. For instance, a gene therapy product, Zynteglo, developed by Bluebird Bio, faced delays and substantial costs during its regulatory review before receiving approval in Europe. Such regulatory challenges can slow the introduction of innovative treatments, impacting the availability of new options for patients and hindering overall market growth.

Global Sickle Cell Disease Market Scope and Trends

• The Food and Drug Administration has granted approval for a CRISPR-based treatment aimed at addressing beta thalassemia, a genetic blood disorder. This therapy is the same potentially curative option that received FDA clearance in December for the treatment of sickle cell disease.
• New sickle cell disease drug voxelotor approved by National Institute for Health and Care Excellence (Nice) for use in England.
• The introduction of novel therapies like Crizanlizumab and Voxelotor marks a substantial advancement in the management of Sickle Cell Disease, as these medications specifically address underlying disease mechanisms and enhance patient outcomes.
• Next-generation sequencing (NGS) offers a breakthrough in the Sickle Cell Disease market by enabling precise genetic profiling and enhancing diagnostic accuracy. Advanced technology allows for early detection and more accurate identification of genetic mutations, leading to better-targeted treatment strategies.
• Innovations like CRISPR-Cas9 are transforming the Sickle Cell Disease market by directly targeting and correcting genetic mutations responsible for the condition. CRISPR-Cas9, a cutting-edge gene-editing technology holds the promise of potentially curative treatments, addressing the root cause of various Sickle Cell Disease types.

Global Sickle Cell Disease Market Regional Analysis – Market Trends

Key Insights

• North America, spearheaded by the United States and Canada, plays a significant role in the Global Sickle Cell Disease Market, propelled by its sophisticated healthcare infrastructure, considerable investments in research, and a notable incidence of Sickle Cell Disease within certain demographics. Recent approvals by the U.S. FDA for groundbreaking therapies like Voxelotor and Crizanlizumab underscore the region's commitment to enhancing treatment alternatives and patient outcomes.
• In Europe, nations including the United Kingdom, Germany, and France are experiencing heightened market activity, driven by favorable healthcare policies and vigorous research efforts. The European Union's dedication to financing research on Sickle Cell Disease and enhancing treatment accessibility plays a significant role in the market expansion within the region.
• Asia-Pacific is experiencing the highest growth rate in the Sickle Cell Disease Market, with notable developments in countries like India and Thailand. For instance, India has launched National Sickle Cell Anemia Control Program which aims to enhance early detection, improve patient care, and increase treatment accessibility across the country.

Global Sickle Cell Disease Market Leading Players

• Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• Allergan (Ireland)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Hikma Pharmaceuticals PLC (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Bayer AG (Germany)
• Boehringer Ingelheim International GmbH (Germany)
• Reddy's Laboratories Ltd. (India)
• Gilead Sciences, Inc. (U.S.)
• Amgen Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• AbbVie Inc. (U.S.)
• Lupin (India

Global Sickle Cell Disease Market Recent Developments

• In March, 2024 Pharmaceutical manufacturers Akums announced that it had launched the India’s first indigenous hydroxyurea oral solution, used for the treatment of sickle cell disease in children. Akums said the drug will be provided to the government at the cost of R600, which is nearly 1% of the R77,000 that the medicine currently available globally costs.
• In June, 2024, The Indian Council of Medical Research (ICMR) has invited Expressions of Interest (EoI) from eligible organizations for the “joint development and commercialization” of low dose or pediatric oral formulation of hydroxyurea to treat sickle cell disease in India.
• В августе 2024 года в рамках клинического исследования RUBY, целью которого является оценка эффективности, безопасности и переносимости препарата reni-cel у 45 человек с тяжелой серповидноклеточной анемией (SCD) в возрасте от 12 до 50 лет, был завершен набор в подростковую группу для участия в клиническом исследовании RUBY фазы 1/2/3, в котором тестируется терапия по редактированию генов renizgamglogene autogedtemcel (reni-cel) компании Editas Medicine у ​​людей с серповидноклеточной анемией (SCD).
• В июне 2024 года FDA создало новый специализированный офис для принятия широкого спектра решений, касающихся клеточной и генной терапии, включая потенциальное внедрение первой терапии CRISPR, а также первой генной терапии мышечной дистрофии Дюшенна.

SKU-53472